These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 34787897)

  • 1. Two years into COVID-19 - Lessons in SARS-CoV-2 and a perspective from papers in FEBS Letters.
    Greber UF
    FEBS Lett; 2021 Dec; 595(23):2847-2853. PubMed ID: 34787897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19: morphology and mechanism of the SARS-CoV-2, global outbreak, medication, vaccines and future of the virus.
    Bhattacharyya P; Das S; Aich S; Sarkar J
    Front Biosci (Elite Ed); 2021 Dec; 13(2):272-290. PubMed ID: 34937314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular host factors for SARS-CoV-2 infection.
    Baggen J; Vanstreels E; Jansen S; Daelemans D
    Nat Microbiol; 2021 Oct; 6(10):1219-1232. PubMed ID: 34471255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic.
    Vlachakis D; Papakonstantinou E; Mitsis T; Pierouli K; Diakou I; Chrousos G; Bacopoulou F
    Food Chem Toxicol; 2020 Dec; 146():111805. PubMed ID: 33038452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.
    Shagufta ; Ahmad I
    Eur J Med Chem; 2021 Mar; 213():113157. PubMed ID: 33486200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human coronaviruses and therapeutic drug discovery.
    Song LG; Xie QX; Lao HL; Lv ZY
    Infect Dis Poverty; 2021 Mar; 10(1):28. PubMed ID: 33726861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
    Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
    Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
    Gupta VK; Murthy MK; Patil S
    Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host proviral and antiviral factors for SARS-CoV-2.
    Lv L; Zhang L
    Virus Genes; 2021 Dec; 57(6):475-488. PubMed ID: 34510331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An all-out assault on SARS-CoV-2 replication.
    Hay RT
    Biochem J; 2021 Jul; 478(13):2399-2403. PubMed ID: 34198321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.
    Fröba M; Große M; Setz C; Rauch P; Auth J; Spanaus L; Münch J; Ruetalo N; Schindler M; Morokutti-Kurz M; Graf P; Prieschl-Grassauer E; Grassauer A; Schubert U
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.
    Hall MD; Anderson JM; Anderson A; Baker D; Bradner J; Brimacombe KR; Campbell EA; Corbett KS; Carter K; Cherry S; Chiang L; Cihlar T; de Wit E; Denison M; Disney M; Fletcher CV; Ford-Scheimer SL; Götte M; Grossman AC; Hayden FG; Hazuda DJ; Lanteri CA; Marston H; Mesecar AD; Moore S; Nwankwo JO; O'Rear J; Painter G; Singh Saikatendu K; Schiffer CA; Sheahan TP; Shi PY; Smyth HD; Sofia MJ; Weetall M; Weller SK; Whitley R; Fauci AS; Austin CP; Collins FS; Conley AJ; Davis MI
    J Infect Dis; 2021 Jul; 224(Supplement_1):S1-S21. PubMed ID: 34111271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses.
    Karam BS; Morris RS; Bramante CT; Puskarich M; Zolfaghari EJ; Lotfi-Emran S; Ingraham NE; Charles A; Odde DJ; Tignanelli CJ
    J Med Virol; 2021 Apr; 93(4):1843-1846. PubMed ID: 33314219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments.
    Parlakpinar H; Gunata M
    Cell Biochem Funct; 2021 Jan; 39(1):10-28. PubMed ID: 32992409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
    Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses.
    Schreiber A; Viemann D; Schöning J; Schloer S; Mecate Zambrano A; Brunotte L; Faist A; Schöfbänker M; Hrincius E; Hoffmann H; Hoffmann M; Pöhlmann S; Rescher U; Planz O; Ludwig S
    Cell Mol Life Sci; 2022 Jan; 79(1):65. PubMed ID: 35013790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
    van de Leemput J; Han Z
    Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies.
    Campos DMO; Fulco UL; de Oliveira CBS; Oliveira JIN
    J Evid Based Med; 2020 Nov; 13(4):255-260. PubMed ID: 33058394
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.